Patents by Inventor Peter Guzzo
Peter Guzzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230105412Abstract: The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.Type: ApplicationFiled: March 16, 2021Publication date: April 6, 2023Inventors: David MANNING, Peter GUZZO
-
Patent number: 10231953Abstract: The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.Type: GrantFiled: December 16, 2015Date of Patent: March 19, 2019Assignee: Zenith Epigenetics Ltd.Inventors: Olesya Kharenko, Peter Ronald Young, Samuel David Brown, Bryan Cordell Duffy, Shuang Liu, Peter Guzzo
-
Publication number: 20170360760Abstract: The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.Type: ApplicationFiled: December 16, 2015Publication date: December 21, 2017Inventors: Olesya KHARENKO, Peter Ronald YOUNG, Samuel David BROWN, Bryan Cordell DUFFY, Shuang LIU, Peter GUZZO
-
Publication number: 20170204095Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: ApplicationFiled: April 3, 2017Publication date: July 20, 2017Inventors: Peter GUZZO, Matthew David SURMAN, Alan John HENDERSON, May Xiaowu JIANG, Mark HADDEN, James GRABOWSKI, Alexander USYATINSKY
-
Patent number: 9650378Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: GrantFiled: February 17, 2016Date of Patent: May 16, 2017Assignee: Albany Molecular Research, Inc.Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang, Mark Hadden, James Grabowski, Alexander Usyatinsky
-
Publication number: 20160159798Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: ApplicationFiled: February 17, 2016Publication date: June 9, 2016Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang, Mark Hadden, James Grabowski, Alexander Usyatinsky
-
Patent number: 9296743Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: GrantFiled: March 24, 2014Date of Patent: March 29, 2016Assignee: Albany Molecular Research, Inc.Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang, Mark Hadden, James Grabowski, Alexander Usyatinsky
-
Publication number: 20140206696Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Applicant: Albany Molecular Research, Inc.Inventors: Peter GUZZO, Matthew David SURMAN, Alan John HENDERSON, May Xiaowu JIANG, Mark HADDEN, James GRABOWSKI, Alexander USYATINSKY
-
Patent number: 8716308Abstract: Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5; is H, optionally substituted alkyl, optionally substituted heterocycle, —C(?O)—R6, —C(?O)—O—R7, or —C(?O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH?CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.Type: GrantFiled: January 9, 2009Date of Patent: May 6, 2014Assignee: Albany Molecular Research, Inc.Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, May Xiaowu Jiang, Mark Hadden, James Grabowski, Alexander Usyatinsky
-
Patent number: 8273770Abstract: 5-pyridinone substituted indazoles of the formula and methods of their use are presented.Type: GrantFiled: July 18, 2008Date of Patent: September 25, 2012Assignee: Albany Molecular Research, Inc.Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, Mark Hadden
-
Publication number: 20090082359Abstract: 5-pyridinone substituted indazoles of the formula and methods of their use are presented.Type: ApplicationFiled: July 18, 2008Publication date: March 26, 2009Applicant: AMR TECHNOLOGY, INC.Inventors: Peter Guzzo, Matthew David Surman, Alan John Henderson, Mark Hadden
-
Publication number: 20080207595Abstract: The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.Type: ApplicationFiled: July 17, 2006Publication date: August 28, 2008Applicant: AMR Technology, Inc.Inventors: Bruce Molino, Shuang Liu, Aruna Sambandam, Peter Guzzo, Min Hu, Congxiang Zha, Kassoum Nacro, David Manning, Matthew Isherwood, Kristen Fleming, Wenge Cui, Richard Olson
-
Publication number: 20080146836Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.Type: ApplicationFiled: July 12, 2007Publication date: June 19, 2008Inventors: Thomas Elebring, Peter Guzzo, Anders Holmen, Thomas Olsson, Marianne Swanson, Sverker Von Unge
-
Publication number: 20070021408Abstract: The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.Type: ApplicationFiled: July 17, 2006Publication date: January 25, 2007Applicant: AMR Technology, Inc.Inventors: Bruce Molino, Shuang Liu, Aruna Sambandam, Peter Guzzo, Min Hu, Congxiang Zha, Kassoum Nacro, David Manning, Matthew Isherwood, Kristen Fleming, Wenge Cui, Richard Olson
-
Patent number: 7034176Abstract: Intermediates used in the preparation of compounds of formula I, or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.Type: GrantFiled: December 16, 2004Date of Patent: April 25, 2006Assignee: Astrazeneca ABInventors: Thomas Elebring, Peter Guzzo, Anders Holmén, Thomas Olsson, Marianne Swanson, Sverker Von Unge
-
Publication number: 20060063766Abstract: The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle opType: ApplicationFiled: July 15, 2005Publication date: March 23, 2006Inventors: Bruce Molino, Shuang Liu, Barry Berkowitz, Marlene Cohen, Peter Guzzo, James Beck
-
Publication number: 20060052378Abstract: The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl, benzo[b]thiophenyl, benzoisothiazolyl, benzoisoxazolyl, indazolyl, indolyl, isoindolyl, indolizinyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, benzotriazolyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl, thieno[2,3-b]pyridinyl, thieno[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, indenyl, indanyl, dihydrobenzocycloheptenyl, tetrahydrobenzocycloheptenyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, indolinyl, naphthyl, tetrahydronaphthyl, quinolinyl, isoquinolinyl, 4H-quinolizinyl, 9aH-quinolizinyl, quinazolinyl, cinnolinyl, phthalazinyl, quinoxalinyl, benzo[1,2,3]triazinyl, benzo[1,2,4]triazinyl, 2H-chromenyl, 4H-chromenyl, and a fused bicyclic carbocycle or fused bicyclic heterocycle opType: ApplicationFiled: July 15, 2005Publication date: March 9, 2006Inventors: Bruce Molino, Shuang Liu, Peter Guzzo, James Beck
-
Publication number: 20050143427Abstract: This invention relates to a compound which is [b]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [b]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [b]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 12, 2004Publication date: June 30, 2005Inventors: Nicole Barvian, Cleo Connolly, Peter Guzzo, James Hamby, James Hicks, Matthew Johnson, Van-Duc Le, Lorna Mitchell, William Roark
-
Publication number: 20050137414Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.Type: ApplicationFiled: December 16, 2004Publication date: June 23, 2005Inventors: Thomas Elebring, Peter Guzzo, Anders Holmen, Thomas Olsson, Marianne Swanson, Sverker Unge
-
Publication number: 20050137215Abstract: This invention relates to a compound which is [c]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [c]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [c]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 12, 2004Publication date: June 23, 2005Inventors: Peter Guzzo, James Hamby, Matthew Johnson, Van-Duc Le, John Mangette, Rajesh Shenoy, Michael Stier